Physician profile
Anne B Mitchell
NPI 1497818470
$4,252.52
in general payments reported to CMS, 2019-2025
23 companies · $790 in 2025
The $790 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $499 · 2023: $1,046 · 2024: $1,754 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,590.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $609.65 | 2023-2025 | |
| Glaxosmithkline, LLC. | $553.31 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $333.10 | 2022-2025 | |
| Lilly USA, LLC | $326.03 | 2022-2025 | Jardiance, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $301.03 | 2022-2024 | Airsupra, Breztri |
| Incyte Corporation | $298.52 | 2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.40 | 2022-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Amgen INC. | $191.93 | 2023-2024 | Evenity, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $169.85 | 2022 | |
| Novo Nordisk INC | $165.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $162.28 | 2021 | |
| Boston Scientific Corporation | $145.10 | 2022-2025 | Watchman Flx |
| Amneal Pharmaceuticals LLC | $138.13 | 2022-2024 | Unithroid |
| Exact Sciences Corporation | $137.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $95.73 | 2025 | Aptima |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.73 | 2023-2025 | Rotateq, Capvaxive, M-M-R II |
| Medtronic, INC. | $69.28 | 2024-2025 | Inpen Smart Insulin Delivery System |
| Idorsia Pharmaceuticals US INC | $67.85 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $66.42 | 2023-2025 | |
| Abbott Laboratories | $30.29 | 2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $29.19 | 2022-2023 | Eliquis |
| Axsome Therapeutics, INC. | $19.42 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $16.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.